- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Unmet Needs for Bronchiectasis Exacerbations
Panelists discuss how reducing bronchiectasis exacerbations requires standardized definitions, tailored antibiotic approaches, and increased airway clearance, while addressing underlying conditions and ongoing research into optimal treatment protocols.
EP: 1.Common Symptoms Seen With Bronchiectasis
EP: 2.Examining The Pathophysiology Of Bronchiectasis
EP: 3.Exploring the Impact of Bronchiectasis Exacerbations
EP: 4.Analyzing Treatment-Refractory Patients
EP: 5.Common Causes of Bronchiectasis
EP: 6.Airway Clearance Techniques and Antibiotics for Patients With Bronchiectasis
EP: 7.Unmet Needs for Bronchiectasis Exacerbations
EP: 8.Ideal Candidates for Bronchiectasis Surgeries
Clinical Brief: Antibiotic Management in Bronchiectasis Exacerbations
Main Discussion Topics
- Antibiotics are a key component of exacerbation management and sometimes chronic therapy.
- Antibiotic selection should be guided by regular sputum cultures and patient history.
- Patient education about exacerbation recognition is crucial for timely intervention.
Key Points for Physicians
- Implement bronchiectasis action plans to help patients recognize exacerbation symptoms.
- Encourage regular sputum sample collection to guide antibiotic selection.
- Consider chronic, suppressive inhaled antibiotics for Pseudomonas aeruginosa.
- Monitor for nontuberculous mycobacterial (NTM) infection, especially in patients on chronic macrolides.
- In select patients, provide antibiotic “rescue packs” for patient-initiated treatment of exacerbations.
Notable Insights
Chronic macrolide therapy is often used for immunomodulatory and anti-inflammatory effects rather than antimicrobial properties but requires careful monitoring for development of NTM resistance.
Clinical Significance
A balanced approach to antibiotic management includes appropriate acute treatment of exacerbations, selective use of chronic suppressive therapy, and vigilant monitoring to prevent resistance.
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
May 22nd 2025FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Read More
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More
